27.3 C
Vientiane
Tuesday, September 9, 2025
spot_img
Home Blog Page 4

Luda Technology Group Limited (LUD.US) Forges Strategic Partnership with Top Chinese Shipbuilders To Advance Green Shipping Localization and High-End Development

HONG KONG, Sept. 9, 2025 /PRNewswire/ — Luda Technology Group Limited and its subsidiaries (the “Luda Technology or Company“, NYSE: LUD.US) announced that its subsidiary, Luda (Taian) Industrial Company Limited (the “Luda Taian”), has signed a series of strategic cooperation agreements with several leading domestic shipbuilding enterprises, including China State Shipbuilding Corporation (CSSC), Haiting (Nantong) Shipbuilding Company, Limited, and COSCO Shipping Heavy Industry Company, Limited, to jointly carry out the research and development (R&D), as well as manufacturing of specialty-material flanges and pipe fittings for ammonia-fueled vessels. This initiative marks an important step forward in the Chinese shipbuilding industry’s efforts to achieve supply chain autonomy and high-end transformation in critical components.

With the continued implementation of new environmental regulations by the International Maritime Organization (IMO), green and low-carbon development has become an inevitable trend in the global shipping industry. The development of vessels powered by new clean fuels, such as ammonia, hydrogen, and methanol has become a focal point across the maritime sector.  As a professional manufacturer holding a full range of certifications from leading international classification societies including DNV (Norwegian), ABS (American), CCS (Chinese), LR (British Lloyd’s), and BV (French), Luda Taian leverages its deep technical expertise in special alloy materials to provide partner shipyards with high-performance, highly reliable flange and piping connection solutions.

Under the agreements, Luda Taian will become a core supplier to the shipbuilders, delivering a full portfolio of certified products for high value-added vessel types currently under construction, such as LNG (liquefied natural gas) carriers, ultra-large container ships, chemical tankers, and luxury cruise ships. The parties will also establish joint technical R&D teams to drive innovation in areas such as new material applications, advanced process development, and digital supply chain management, helping China’s shipbuilding industry meet the challenges and opportunities of a greener and smarter future.

Given the high corrosiveness and hydrogen embrittlement risks of ammonia fuel on metal materials, traditional carbon and stainless steels fall short of the stringent requirements. Luda Taian has proactively invested in testing ammonia-resistant materials, including high-nickel alloys and special stainless steels, along with the development of corresponding welding and heat treatment processes. The company’s advanced physical and chemical laboratories and testing centers enable comprehensive performance testing and life-cycle assessment of new material samples, ensuring all products meet the most rigorous international standards.

In this regard, Mr. Sun Yanru, R&D Director of Luda Taian, emphasized: “Green-powered vessels pose revolutionary requirements for critical components. We must plan ahead, work with leading partners on joint R&D, and co-define the technical standards for next-generation products in order to take the initiative in global competition.”

Meanwhile, Mr. Ma Biu, Chief Executive Officer of Luda Technology, stated: “This in-depth collaboration with China’s ‘national team’ and leading enterprises in shipbuilding marks a critical step in Luda Technology’s transformation from a component manufacturer to a ‘technology solution provider.’ We will continue to increase investment in R&D to ensure that every product delivered meets the most stringent international standards, and together with our industry partners, jointly define the technical standards for next-generation green vessels, thereby elevating the position of Chinese manufacturing in the global high-end marine equipment sector.”

This cooperation not only enhances the security and localization level of China’s shipbuilding supply chain but also demonstrates Luda Technology’s leadership and technical strength in the high-end metal products sector. The Company will continue to deepen industrial collaboration to support the development of green shipping initiatives in China and globally.

About Luda Technology Group Limited (NYSE: LUD.US)
As a manufacturer and trader of stainless steel and carbon steel flanges and pipe fittings, Luda Technology Group Limited is headquartered in Hong Kong, with its production base located in Taian, Shandong Province, China. The Company’s history began with its subsidiary, Luda Development Limited which was incorporated in 2004 and is principally engaged in the trading of steel flanges and pipe fittings. In 2005, the Company expanded its business further upstream by establishing another subsidiary, Luda (Taian) Industrial Company Limited, which commenced the manufacturing of flanges and pipe fittings with a self-owned factory in China.

Luda Technology is principally engaged in (i) the manufacturing and sale of stainless steel and carbon steel flanges and pipe fittings products; and (ii) the trading of steel pipes, valves, and other steel piping products. The Company’s sales network comprises customers in China, South America, Australia, Europe, Asia (excluding China), and North America and with a customer base includes manufacturers and traders from the chemical, petrochemical, maritime, and manufacturing industries.

For more information, please visit https://www.ludahk.com/en.

 

Neo Space Group (NSG) to Acquire Display Interactive, Setting New Standards in In-Flight Connectivity for Airlines and Passengers

  • Upon closing, the acquisition will see Display Interactive become part of NSG.
  • PIF’s NSG expands satellite communications and in-flight connectivity capabilities to serve global markets and meet Saudi Arabia’s growing demand for advanced digital communications, in line with Vision 2030.

RIYADH, Saudi Arabia, Sept. 9, 2025 /PRNewswire/ — Neo Space Group (NSG), a PIF company and Saudi Arabia’s leading commercial space services provider, announced today that it has entered into a definitive agreement to acquire Display Interactive (DI), a recognized innovator in wireless in-flight entertainment and connectivity (IFEC). The acquisition will strengthen NSG’s position in the aviation market as a premier provider of integrated, multi-orbit solutions, underpinned by intelligent bandwidth management and truly global coverage. By combining cutting-edge satellite and digital technologies, NSG will deliver faster, more reliable inflight connectivity (IFC) – enhancing passenger experiences while enabling airlines to optimize operations and unlock new service opportunities.

Neo Space Group (NSG) to Acquire Display Interactive, Setting New Standards in In-Flight Connectivity for Airlines and Passengers
Neo Space Group (NSG) to Acquire Display Interactive, Setting New Standards in In-Flight Connectivity for Airlines and Passengers

NSG and DI began collaborating on product development in 2023. Building on this foundation, the partnership was further strengthened in May 2024 when DI introduced the Skywaves® satellite connectivity system in cooperation with NSG. The acquisition will mark the next stage in this collaboration, accelerating the evolution of IFC.

By integrating DI’s advanced technology and product portfolio, NSG is delivering a fully unified IFC solution – combining intelligent traffic management through Skywaves® with a seamless digital passenger experience via its SkyFly end-user portal. Supported by the SES Open Orbits™ network, NSG’s system intelligently routes traffic across multiple satellite providers, ensuring uninterrupted, high-speed connectivity for airlines and passengers worldwide.

This end-to-end approach simplifies IFC deployment for airlines, providing a faster and more efficient path to next-generation connectivity. Additionally, NSG collaborates with leading aerospace partners to enable smooth integration across airline fleets, making advanced IFC more accessible than ever.

Martijn Blanken, CEO of NSG, stated: “The IFC sector is evolving rapidly, and remaining competitive requires a strong customer focus, continuous innovation, and adaptability. Acquiring DI strengthens our ability to deliver cutting-edge connectivity solutions while ensuring passengers enjoy an unparalleled in-flight experience with seamless connectivity, high-speed internet, and real-time entertainment and communication.”

Tarek El Mitwalli, CEO of Display Interactive, added: “Joining forces with Neo Space Group allows us to open a new chapter, scaling our technology and expanding our impact in global aviation. Together, we will push the boundaries of innovation and connectivity in the most agile way.”

As part of its commitment to advancing the ambitions of Saudi Arabia’s Vision 2030, NSG continues to invest in next-generation satellite and digital technologies, while fostering the growth of the national space industry. This acquisition, which is subject to customary closing conditions, builds on NSG’s established capabilities in satellite communications and IFC, reinforcing its role as a key enabler of secure, multi-orbit connectivity and a catalyst for the Kingdom’s leadership in the global space and aerospace domain.

To know more about NSG: www.neospacegroup.com

CONTACT: Raouf Khalife, rkhalife@neospacegroup.com, +966 50 136 25 33

Photo – https://laotiantimes.com/wp-content/uploads/2025/09/nsg_to_acquire_display_interactive.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/09/nsg_logo.jpg

 

 

Aduna and BTS Partner to Tackle Fraud Prevention and Identity Verification

Exploring global opportunities starting with SIM Swap and Number Verification APIs

PLANO, Texas, Sept. 9, 2025 /PRNewswire/ — Aduna, the global aggregator of standardized network APIs, and Business Telecommunications Services, Inc. (BTS), a leading provider, technology enabler, and trusted partner to CommTech players, today announced a strategic collaboration to enhance fraud prevention and identity verification services. The partnership will initially explore opportunities in high growth and emerging markets such as Asia and South America, focusing on SIM Swap detection and Number Verification use cases.

BTS is partnering with Aduna to strengthen its portfolio in mobile identity and fraud protection by integrating Aduna’s standardized network API capabilities. The collaboration will introduce advanced services such as SIM Swap detection and Number Verification, complementing BTS’s existing solutions for identity verification, user authentication, and customer engagement including OTP, Mobile ID, Silent SMS Authentication, Branded Calls, and Number Anonymization.

“Fraud protection and mobile identity are critical challenges for our customers,” said Andres Proano, Chief Revenue Officer (CRO), BTS. “By combining our award-winning S1 Platform with Aduna’s standardized network API capabilities, we can deliver powerful new services that address pressing needs like SIM Swap detection and Number Verification, enabling high growth regions.”

“This collaboration underscores Aduna’s mission to enable a trusted, global ecosystem for identity and security,” said Anthony Bartolo, CEO, Aduna. “Partnering with BTS allows us to expand our reach into some of the world’s most dynamic digital economies and emerging markets.”

The partnership highlights a significant opportunity for both companies to shape the next wave of fraud prevention and identity innovation. By tapping into fast-growing emerging markets, Aduna and BTS aim to showcase the value of secure communications and build momentum for global adoption.

About BTS

Owned by BTS Group, BTS is a leading global provider, technology enabler, and trusted partner to CommTech players. Leveraging its proprietary S1 Platform, an international network of 400+ partners, and 180+ direct links, BTS delivers advanced solutions across Global Connectivity, Smart Voice, Identity, Managed Communications, Omnichannel, Protection, and Analytics driving growth for Operators, MNOs, CPaaS, and hyperscalers. BTS powers 18+ billion voice minutes annually, enables the delivery of 500M+ messages worldwide, and provides extensive cloud numbers coverage in 90+ hard-to-reach markets, ensuring seamless and secure global communications.

For more information, visit bts.io or contact Paula Ruiz, BTS Communications Team at pruiz@bts.io 

About Aduna

Aduna is a landmark venture between some of the world’s leading telecom operators and Ericsson, dedicated to enabling developers worldwide to accelerate innovation by leveraging networks to their full potential via common network Application Programming Interfaces (APIs). Its venture partners include AT&T, Bharti Airtel, Deutsche Telekom, e&, KDDI, Orange, Reliance Jio, Singtel, Telefonica, Telstra, T-Mobile, Verizon and Vodafone. By combining network APIs from multiple operators globally under a unified platform based on the CAMARA open-source project, driven by the GSMA and the Linux Foundation, Aduna provides a standardized platform to foster collaboration, enhance user experiences, and drive industry growth.

To find out more about network APIs and Aduna, visit adunaglobal.com.

Media Contact: 
Email: MediaRelations@adunaglobal.com
Tel: +46 10 719 69 92 

Erayak Power Solution Announces Receipt of Nasdaq Delisting Notice Subject to Hearing Request

WENZHOU, China, Sept. 9, 2025 /PRNewswire/ — Erayak Power Solution Group Inc. (Nasdaq: RAYA), a leading manufacturer, designer, and exporter of high-quality products in the power supply industry, today announced it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) on September 3, 2025, notifying that the Company is not in compliance with Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”), as the Company’s securities had a closing bid price of $0.10 or less for the last ten consecutive trading days. The letter indicated that, as a result, the Nasdaq staff determined to delist the Company’s securities from The Nasdaq Global Market (the “Delisting Determination”).

The letter also indicated that the bid price of the Company’s Class A ordinary shares had closed at less than $1 per share over the previous 30 consecutive business days, and as a result, the Company is not in compliance with Listing Rule 5450(a)(1) (the “Rule”). Normally, a company is provided 180 calendar days to regain compliance with the Rule in accordance with Listing Rule 5810(c)(3)(A). However, the Nasdaq determined that the Company’s securities also had a closing bid price of $0.10 or less for the last ten consecutive trading days. Accordingly, the Company became subject to the provisions contemplated under the Low Priced Stocks Rule. As a result, the Nasdaq determined to delist the Company’s securities from The Nasdaq Capital Market. The Company was provided until September 10, 2025 to request an appeal of the Delisting Determination to the Hearings Panel (the “Panel”). If the Company fails to request an appeal by September 10, 2025, trading of the Company’s securities will be suspended at the opening of business on September 12, 2025, and a Form 25-NSE will be filed with the SEC, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market.

The Company intends to request such hearing to appeal the Delisting Determination before September 10, 2025, which will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision.

The Company is considering all potential options available to it to regain compliance with the aforementioned rules, including seeking shareholders’ approval for a reverse stock split.

About Erayak Power Solution Group Inc.

Erayak specializes in the manufacturing, research and development, and wholesale and retail of power solution products. Erayak’s product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery and smart chargers, and custom-designed products. Our products are used principally in agricultural and industrial vehicles, recreational vehicles, electrical appliances, and outdoor living products. Our goal is to be the premier power solutions brand and a solution for mobile life and outdoor living. For more information, visit www.erayakpower.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Email: investor@erayakpower.com 

Maxx Upgrades Affordable SIM-Only Plan with 5G

SINGAPORE, Sept. 9, 2025 /PRNewswire/ — M1’s Maxx provides some of Singapore’s most affordable SIM-Only plans, now with 5G connectivity for all new and existing customers. As part of a limited-time offer, this upgrade is available at no cost to all customers.

Why Maxx SIM-Only Plans Have Been Upgraded to 5G

The new 5G SIM upgrade is part of Maxx‘s commitment to providing a seamless data experience that is both affordable and accessible to a wider audience. According to M1’s Media Alert, the Maxx network is “Powered by M1’s ultra-fast 5G network, consistently ranked among the best in Singapore“, and “delivers a high-performance mobile experience wherever you are.”

Maxx SIM-Only Plans Eligible for 5G Upgrade

M1 states that “Maxx plans are built for customers who want simplicity, flexibility and great value”, which is why the free 5G upgrade is available to all Maxx SIM-Only plans S$10 and above. The S$10 Maxx 5G SIM-Only Plan comes with:

  • 400GB Local Data in Singapore and Malaysia
  • 16GB Roaming Data (13GB for APAC, 3GB for International)
  • Up to 300 IDD Minutes
  • 500 minutes of talktime for local outgoing calls
  • Unlimited local incoming calls
  • 50 local SMS

How to Upgrade a Maxx SIM-Only Plan to 5G

Customers can check their handset, SIM, and plan eligibility by navigating to “Account” and then “Check Your 5G Readiness” within the Maxx App.

Existing customers can upgrade their Maxx SIM to 5G via two methods:

  • Maxx App: Customers who prefer a 5G eSIM can upgrade instantly by logging into their Maxx App and tapping on: Account > SIM Management > Upgrade to 5G eSIM
  • In-Person: Customers can visit designated M1 Shops or SIM exchange roadshows to get a physical 5G SIM for their phone. Users who would like to visit a roadshow for a physical 5G SIM can visit the following link for a list of roadshow locations.

As a trusted choice for mobile users across Singapore, Maxx looks forward to delivering a speedy and reliable mobile experience for its customers with the 5G upgrade for its affordable SIM-Only plans.

About M1

M1, a subsidiary of Keppel Ltd., is Singapore’s first digital network operator, providing a suite of communications services, including mobile, fixed line and fibre offerings, to over two million customers.

Since the launch of its commercial services in 1997, M1 has achieved many firsts – becoming one of the first operators to be awarded one of Singapore’s two nationwide 5GSA standalone network licences, first operator to offer nationwide 4G service, as well as ultra high-speed fixed broadband, fixed voice and other services on the Next Generation Nationwide Broadband Network (NGNBN).

M1’s mission is to drive transformation and evolution in Singapore’s telecommunications landscape through cutting-edge technology and made-to-measure offerings. For more information, visit m1.com.sg

Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC

SHANGHAI, Sept. 9, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the presentation of new findings on its leading assets, ZEGFROVY® (sunvozertinib) and golidocitinib, in non-small cell lung cancer (NSCLC) at the 2025 World Conference on Lung Cancer (WCLC), held September 6–9 in Barcelona, Spain.

ZEGFROVY: Targeting EGFR exon20ins and a wide spectrum of EGFR mutations

The latest data from the multinational pivotal WU-KONG1 Part B (WU-KONG1B) study for ZEGFROVY were presented in an oral session at the conference and simultaneously published in the Journal of Clinical Oncology. Based on results from WU-KONG1B, ZEGFROVY received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2025 as the only targeted oral therapy for NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).

ZEGFROVY demonstrated a favorable benefit/risk profile in patients with platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The study showed robust and durable antitumor activity with a manageable safety profile. (#MA08.01).

In addition to the oral presentation, multiple studies of ZEGFROVY were presented at the WCLC, highlighting its potential across a broad range of NSCLC patients, including those with EGFR exon20ins across all lines of therapy, uncommon EGFR and HER2 mutations, EGFR-sensitive mutation and co-mutations, and EGFR mutations resistant to EGFR TKIs. Both monotherapy and combination regimens were evaluated.

In EGFR exon20ins NSCLC, ZEGFROVY demonstrated promising antitumor efficacy and a tolerable safety profile across first- and second- line, as well as adjuvant and neoadjuvant treatment settings.

  • ZEGFROVY combined with anlotinib achieved an objective response rate (ORR) of over 80% and a disease control rate (DCR) of 100% in treatment-naïve EGFR exon20ins NSCLC (#P3.12.43).
  • In previously treated patients, ZEGFROVY combined with bevacizumab achieved a DCR of 100%, with target tumor lesion shrinkage observed in 85.7% of patients. With a median follow-up of 15.2 months, the median duration of response (DoR) was 19.1 months, and three patients (3/14) remained in response at the data cut-off (#P2.10.13).

Real-world cases supported the potential of ZEGFROVY in early- and advanced- stage NSCLC patients with EGFR exon20ins.

  • As a neoadjuvant therapy, ZEGFROVY showed encouraging clinical benefit, with all 3 patients achieving an obvious partial response (PR) before surgery. (#EP.07.49).
  • In the adjuvant setting, ZEGFROVY showed sustained efficacy and tolerable safety profiles, helping patients successfully pass the 1-year after surgery, a peak period for disease recurrence (#EP.07.55).
  • In the first-line maintenance setting, ZEGFROVY showed sustained efficacy and safety in lung adenocarcinoma patients who were intolerant to immunotherapy and chemotherapy (#EP.12.47).

In NSCLC patients harboring uncommon EGFR mutations, ZEGFROVY combined with anlotinib demonstrated promising efficacy, including one patient who achieved complete remission of intracranial lesions (#P3.12.43). In a separate real-world case series, ZEGFROVY exhibited clinical efficacy in advanced NSCLC with HER2 exon20ins, with tumor shrinkage obviously observed post-prior treatment failures (#EP.12.46).

In treatment-naïve NSCLC patients with EGFR-sensitive mutation and co-mutations, ZEGFROVY in combination with anlotinib achieved an ORR of 77.8% and a DCR of 100% (#P3.12.22). In NSCLC patients with EGFR mutations who failed prior EGFR-TKI therapies, ZEGFROVY, both as monotherapy (#EP.12.43) and in combination with chemotherapy (#P3.12.47), was well tolerated and demonstrated encouraging antitumor activity.

Golidocitinib: Janus kinase 1 (JAK1) only inhibitor Plus Anti-PD-1 in Anti-PD-1 Treated Advanced NSCLC

Resistance to first-line immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) leads to limited treatment options and poor prognosis. Preclinical and early clinical data have shown synergistic effects between JAK inhibitors and anti-PD-1, suggesting a promising therapeutic strategy in this population. Golidocitinib in combination with anti-PD-1 was being evaluated in immune-resistant NSCLC patients. The study showed a well-tolerated profile, with no DLTs observed in the dose-escalation phase. Ongoing enrollment and data collection will provide deeper insights into clinical utility of golidocitinib (#P1.11.74).

Dr. Xiaolin Zhang, CEO of Dizal, remarked, “Dizal is advancing therapies for patients with NSCLC across EGFR exon 20 insertion, uncommon and EGFR-sensitizing mutations to address significant unmet medical needs. Through scientific innovation, we aim to deliver safe, effective and transformative treatments to patients worldwide.”

–      End    –

About ZEGFROVY®(sunvozertinib)

ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The China approval is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication.

In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations (such as G719X, L861Q, etc.), as well as HER2 exon20ins.

ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.

WU-KONG28, a phase III, multinational, randomized study assessing ZEGFROVY as a first-line treatment for patients with EGFR exon20ins NSCLC, has completed enrollment across 16 countries and regions.

Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology.

About golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).

At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.

Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com

Business Development: bd@dizalpharma.com

Media Contact: pr@dizalpharma.com

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry

  • End-to-end Green CRDMO solutions to enable global clients for broader positive impact
  • Span from biologics research, development, manufacturing, and overall operations
  • Integration with lean management and digitalization for continuous excellence
  • A comprehensive ecosystem featuring diverse energy-saving and carbon-reduction initiatives

SHANGHAI, Sept. 9, 2025 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), recently launched the “WuXi Biologics Green CRDMO White Paper” at its first CRDMO+ Open Day event, sharing the end-to-end Green CRDMO solution for biologics and driving the sustainable development of the global biologics industry supply chain. Last November, the company’s Green CRDMO solution was also featured in the “20 Case Examples for 20 Years” report initiated by the United Nations Global Compact, making it the only case in the pharmaceutical industry to receive this honor.

Along with an overall introduction to the company’s strategic approach toward sustainability and climate change, the White Paper details WuXi Biologics’ green innovation technologies across the research, development and manufacturing of biologics, and showcases the significant carbon reduction achieved through green operations. A total of 242 energy-saving cases are compiled in the White Paper, spanning five key energy-saving scenarios, 12 typical energy systems, and 25 technology categories within the industry.

In addition, the paper highlights how the integration of lean management and digitalization with sustainability enhances resource and energy efficiency, while driving continuous improvement. In 2024, over 90% of the company’s completed Kaizen projects achieved ESG benefits, including reductions in carbon emission, water consumption and waste generation.

With a deep understanding of the importance of tackling climate change, WuXi Biologics has adopted a comprehensive, integrated strategy with measurable targets and a well-defined roadmap. Recently, the company announced a new target matrix approved by SBTi, an acknowledgement that further inspires its steadfast dedication to leading the way to a net-zero economy.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are pleased to release the Green CRDMO White Paper with the aspiration that our insights and best practices will inspire and empower the whole industry to drive sustainable progress. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to deliver meaningful and far-reaching impacts.”

As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security “A List” and Supplier Engagement Assessment “A List”, and awarded a CDP Climate Change leadership-level “A-” score for two consecutive years; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain. 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts

ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

KuCoin Pay Launches On-Chain Payment Solution for Merchants and Consumers, Advancing Responsible Innovation to Enhance Crypto Accessibility for All

PROVIDENCIALES, Turks and Caicos Islands, Sept. 9, 2025 /PRNewswire/ — KuCoin, a leading global cryptocurrency exchange, today announced that its crypto payment arm, KuCoin Pay, has introduced its On-Chain Payment Solution. This empowers merchants and consumers with a decentralized framework for direct cryptocurrency payments on the blockchain. By leveraging a comprehensive AML compliance system, it enables seamless wallet-to-wallet transactions without intermediaries and delivering the inherent speed, security, and transparency of decentralized systems.


Backed by KuCoin’s regulated and reliable ecosystem, the solution revolutionizes crypto commerce. It offers seamless on-chain payments through direct wallet-to-wallet transfers, enabling instant settlements. With multi-chain support, KuCoin Pay is compatible with major blockchains and accommodates preferred assets such as BTC, USDT, USDC, and more. Users benefit from low-cost structures, paying only gas fees, while merchants enjoy seamless access to the global market along with easy-to-integrate APIs and payout functionality.

Designed for adoption by small- and medium-sized merchants—from e-commerce sites to physical retail—the On-Chain Payment Solution features turnkey white-label integration. This allows businesses to launch customized crypto payment systems without developing infrastructure from scratch, preserving brand identity while simplifying onboarding, reducing technical complexity, and accelerating time to market. For merchants, the solution reduces fraud and chargeback risks through irreversible transactions, unlocks access to a fast-growing crypto user base, and creates opportunities for innovative business models. By offering modern payment options, merchants can strengthen customer loyalty while positioning themselves at the forefront of the Web3 and DeFi movement. The white-label advantages deliver a competitive edge over traditional providers. For users, the solution delivers seamless checkout experiences with direct crypto payments, empowering them with greater control over funds. They can choose from a wide range of assets, including BTC, ETH, and stablecoins, and enjoy borderless accessibility wherever they are in the world.

“This On-Chain Payment Solution marks a pivotal advancement in bridging cryptocurrency with everyday commerce. With its turnkey white-label capabilities, it empowers merchants to integrate crypto payments effortlessly while maintaining brand integrity,” said Raymond Ngai, KuCoin Pay Lead. “By prioritizing direct, secure, and cost-effective transactions, we’re not only enhancing trust and efficiency but also driving responsible innovation to make crypto accessible for all.”

About KuCoin Pay

KuCoin Pay is a pioneering merchant payment solution that enables businesses to integrate cryptocurrency transactions for both online and offline sales. Supporting over 50 cryptocurrencies including KCS, USDT, USDC, and BTC, KuCoin Pay delivers fast, secure, and borderless payments to its audience.